TapImmune announces definitive purchase agreement for Senior Secured Convertible Notes totaling $1.53M

TapImmune Inc. (OTCBB:TPIV), a Nevada corporation, announced today that the Company entered into a definitive purchase agreement on May 17, 2010 with accredited investors to place Senior Secured Convertible Notes (collectively, "Notes") totaling $1.53 million.  The net proceeds of the financing will be used for the development of certain partnerships and for general working capital.  The Company expects the transaction to close within two days of the execution of such purchase agreement, subject to the satisfaction of customary closing conditions.

The aggregate original principal amount of the Notes is $1.53 million.  In addition to the gross proceeds to be received for the Notes, an outstanding and due debenture in the original principal amount of $350,000 is also being converted into the Notes.  The holders of the Notes may choose to convert the Notes into common stock at anytime at a conversion price of $.30. Beginning in September 2010, the Notes are payable in nine monthly installments.  The Company can make the amortization payments, at its option, either in cash or, subject to the satisfaction of certain conditions, registered shares of common stock. Along with the Notes, the Company has issued three sets of warrants each with an exercise price of $.30 per share that if fully exercised would result in an additional investment of $5,691,000 before fees and expenses.  The Company will be required to file a registration statement within 30 days of the closing date and will use its reasonable best efforts to cause such registration statement to be declared effective within 120 days of the closing date.  The investors and the placement agent shall receive an aggregate of 18,970,000 warrant shares, 6,775,000 of which will only be issued on a pro-rata basis with the exercise of the Series B Warrants.

Olympus Securities, LLC acted as exclusive placement agent for this transaction.

Source:

TapImmune Inc.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Evident Corporation - Life Sciences. (2019, June 19). TapImmune announces definitive purchase agreement for Senior Secured Convertible Notes totaling $1.53M. News-Medical. Retrieved on July 13, 2024 from https://www.news-medical.net/news/20100518/TapImmune-announces-definitive-purchase-agreement-for-Senior-Secured-Convertible-Notes-totaling-24153M.aspx.

  • MLA

    Evident Corporation - Life Sciences. "TapImmune announces definitive purchase agreement for Senior Secured Convertible Notes totaling $1.53M". News-Medical. 13 July 2024. <https://www.news-medical.net/news/20100518/TapImmune-announces-definitive-purchase-agreement-for-Senior-Secured-Convertible-Notes-totaling-24153M.aspx>.

  • Chicago

    Evident Corporation - Life Sciences. "TapImmune announces definitive purchase agreement for Senior Secured Convertible Notes totaling $1.53M". News-Medical. https://www.news-medical.net/news/20100518/TapImmune-announces-definitive-purchase-agreement-for-Senior-Secured-Convertible-Notes-totaling-24153M.aspx. (accessed July 13, 2024).

  • Harvard

    Evident Corporation - Life Sciences. 2019. TapImmune announces definitive purchase agreement for Senior Secured Convertible Notes totaling $1.53M. News-Medical, viewed 13 July 2024, https://www.news-medical.net/news/20100518/TapImmune-announces-definitive-purchase-agreement-for-Senior-Secured-Convertible-Notes-totaling-24153M.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Olympus Discovery Center brings advanced microscopy to brain research